(Q78200350)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

title

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

main subject

metastatic breast cancer

1 reference

P H Cottu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

L Zelek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

J M Extra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

M Espie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

L Mignot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

F Morvan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

M Marty

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

publication date

1 July 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

page(s)

795-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Construction and validation of a practical prognostic index for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Dose-response in the treatment of breast cancer: a critical review

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

A phase I-II study of intensive-dose adriamycin for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Recent advances in the management of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

High-dose chemotherapy with autologous stem cell support for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Development and validation of prognostic models in metastatic breast cancer: a GOCS study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008353904351

7 January 2021

Identifiers

DOI

10.1023/A:1008353904351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10470426%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference